Intra-Cellular Therapies, Inc. (ITCI)
NASDAQ: ITCI · IEX Real-Time Price · USD
74.86
-0.08 (-0.11%)
At close: Jul 19, 2024, 4:00 PM
75.32
+0.46 (0.61%)
Pre-market: Jul 22, 2024, 5:44 AM EDT
Intra-Cellular Therapies Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for ITCI stock have an average target of 94.83, with a low estimate of 77 and a high estimate of 120. The average target predicts an increase of 26.68% from the current stock price of 74.86.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ITCI stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 6 | 6 | 5 | 5 |
| Buy | 6 | 6 | 5 | 5 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Maintains $94 → $100 | Strong Buy | Maintains | $94 → $100 | +33.58% | Jul 22, 2024 |
| UBS | UBS | Strong Buy → Hold Downgrades $85 → $83 | Strong Buy → Hold | Downgrades | $85 → $83 | +10.87% | Jun 25, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $103 | Buy | Reiterates | $103 | +37.59% | Jun 25, 2024 |
| Mizuho | Mizuho | Strong Buy Maintains $96 → $100 | Strong Buy | Maintains | $96 → $100 | +33.58% | Jun 21, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $107 → $113 | Strong Buy | Maintains | $107 → $113 | +50.95% | Jun 20, 2024 |
Financial Forecast
Revenue This Year
675.98M
from 464.37M
Increased by 45.57%
Revenue Next Year
940.64M
from 675.98M
Increased by 39.15%
EPS This Year
-0.55
from -1.46
EPS Next Year
1.07
from -0.55
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 709.5M | 1.1B | 1.7B | 2.3B | 3.3B |
| Avg | 676.0M | 940.6M | 1.4B | 1.8B | 2.5B |
| Low | 639.0M | 770.3M | 953.5M | 1.4B | 1.7B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 52.8% | 60.8% | 79.3% | 68.2% | 79.9% |
| Avg | 45.6% | 39.2% | 44.3% | 33.5% | 38.3% |
| Low | 37.6% | 14.0% | 1.4% | 1.4% | -5.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.29 | 3.20 | 7.54 | 10.50 | 15.31 |
| Avg | -0.55 | 1.07 | 3.91 | 7.21 | 11.03 |
| Low | -0.87 | -0.41 | 1.34 | 3.43 | 6.33 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 601.5% | 168.3% | 112.4% |
| Avg | - | - | 264.2% | 84.1% | 53.1% |
| Low | - | - | 24.9% | -12.4% | -12.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.